Testolactone treatment of precocious puberty in McCune-Albright syndrome.

Abstract

Current medical and surgical therapies of precocious puberty in McCune-Albright syndrome are often unsatisfactory. We used an aromatase inhibitor, testolactone, to treat precocious puberty in a girl with McCune-Albright syndrome. This child was unresponsive to 28 weeks of treatment with the long-acting agonist of LRH, D-trp6-pro9-NEt-LRH. During testolactone therapy, menses ceased, bone age advancement and height velocity diminished, and plasma oestradiol levels were suppressed. Serum gonadotrophin levels remained in the prepubertal range. Testolactone may be an effective therapy of precocious puberty in girls with McCune-Albright syndrome.

• Authors: C M Foster, O H Pescovitz, F Comite, P Feuillan, T Shawker, D L Loriaux, G B Cutler Jr
• Journal: Acta endocrinologica (Acta Endocrinol (Copenh)) Vol. 109 Issue 2 Pg. 254-7 (Jun 1985) ISSN: 0001-5598 [Print] Denmark
• PMID: 3925675 (Publication Type: Case Reports, Journal Article)

Chemical References

• Triptorelin Pamoate
• Estrone
• Gonadotropin-Releasing Hormone
• Testosterone
• Androstenedione
• Estradiol
• Tryptal
• Testolactone
• Luteinizing Hormone
• Follicle Stimulating Hormone

Topics

• Androstenedione (blood)
• Child, Preschool
• Endocrine System Diseases (drug therapy)
• Estradiol (blood)
• Estrone (blood)
• Female
• Fibrous Dysplasia of Bone (drug therapy)
• Follicle Stimulating Hormone (blood)
• Gonadotropin-Releasing Hormone (analogs & derivatives, therapeutic use)
• Humans
• Luteinizing Hormone (blood)
• Puberty, Precocious (drug therapy)
• Syndrome
• Testolactone (therapeutic use)
• Testosterone (blood)
• Triptorelin Pamoate (analogs & derivatives)